FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Bio­phar­ma’s res­i­dent an­ti­body-drug con­ju­gate ex­pert Seagen has scored a clutch of on­col­o­gy ap­provals in re­cent years, find­ing gold in what are known as “third-gen” AD­Cs. Now, an­oth­er of their part­nered con­ju­gates is ready for prime time.

The FDA on Mon­day hand­ed an ac­cel­er­at­ed ap­proval to Seagen and Gen­mab’s Tiv­dak (ti­so­tum­ab ve­dotin-tftv, or “TV”) in sec­ond-line pa­tients with re­cur­rent or metasta­t­ic cer­vi­cal can­cer who pre­vi­ous­ly pro­gressed af­ter chemother­a­py rather than PD-(L)1 sys­temic ther­a­py, the com­pa­nies said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER